Pfizer has agreed to grant a royalty-free license to sell its anti-coronavirus pill in nearly 100 developing countries around the world.
Under the agreement signed with the Medicines Patent Pool (MPP), a UN-backed public health organization, Pfizer will not receive royalties on the sales of its promising antiviral pill in 95 poorer countries, including the states of Sub-Saharan Africa. The measure allows MPP to grant sub-licenses to “qualified” generic medicine manufacturers in each country.
The countries covered by the deal comprise around 53% of the world’s population, Pfizer said. “We believe oral antiviral treatments can play a vital role in reducing the severity of Covid-19 infections, decreasing the strain on our healthcare systems and saving lives,” Pfizer CEO Albert Bourla said.
We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs.
During its phase-two/three trial, the drug PF-07321332, trademarked as Paxlovid, reduced the risk of hospitalization or death by 89% in Covid-19 patients who took it within three days of symptom onset. The drug is administered in combination with low-dose ritonavir, a medication used to treat HIV/AIDS.
The UN and the World Health Organization (WHO) have long been urging companies to make vaccines and other forms of Covid-19 treatment accessible and affordable for developing countries.
Think your friends would be interested? Share this story!
source: RT
Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.
